Video Experimental Relacionado
Updated: Jul 13, 2026
09:33
A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology
Published on: February 7, 2015
El polimorfismo de la enzima convertidora de angiotensina I/D y el grosor de la pared arterial en una población
M Castellano1, M L Muiesan, D Rizzoni
1Center of Hypertension and Cardiorespiratory Risk Factors, University of Brescia, Italy.
Circulation
|June 1, 1995
Resumen
El genotipo DD de la enzima convertidora de angiotensina I (ACE) está relacionado con el aumento del grosor de la pared de la arteria carótida. Este hallazgo sugiere que el genotipo ACE DD puede ser un factor de riesgo para problemas cardiovasculares.
Área de la Ciencia:
- Genética cardiovascular Genética cardiovascular
- Biología Vascular Biología Vascular
- Investigación de la Hipertensión Investigación de la Hipertensión
Sus antecedentes:
- El polimorfismo de inserción/deleción (I/D) del gen de la enzima convertidora de angiotensina I (ACE), específicamente el alelo D, se ha relacionado con riesgos cardiovasculares como la hipertrofia ventricular izquierda.
- Una hiperactividad genéticamente determinada del sistema renina-angiotensina puede influir en el crecimiento cardíaco y vascular.
Objetivo del estudio:
- Para investigar la relación entre el genotipo ACE I/D y el grosor de la pared de la arteria carótida.
- Evaluar el genotipo ACE I/D como un factor de riesgo potencial para la aterosclerosis subclínica.
Principales métodos:
- Un estudio en el que participaron 199 personas de entre 50 y 64 años de la población general.
- El espesor íntima-media de la arteria carótida se midió mediante ecografía de modo B.
- Se realizó genotipización para el polimorfismo ACE I/D.
Principales resultados:
- El genotipo ACE DD se asoció significativamente con un aumento del grosor íntima-medio de la arteria carótida común (P = .003).
- No se encontró una asociación significativa entre el genotipo ACE I/D y la presencia de placas ateroscleróticas de la carótida.
- El genotipo ACE I/D no se correlacionó con las mediciones de la presión arterial, ni casuales ni ambulatorias.
Conclusiones:
- El genotipo ACE DD puede ser identificado como un factor de riesgo para el desarrollo del engrosamiento común de la carótida íntima-media.
- Esto sugiere un papel potencial para el genotipo ACE en los cambios vasculares tempranos que contribuyen al riesgo cardiovascular.
Videos de Conceptos Relacionados
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...